Stephen Michael Kelsey - 13 Aug 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President, Research and Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
Issuer symbol
RVMD
Transactions as of
13 Aug 2024
Net transactions value
-$648,221
Form type
4
Filing time
15 Aug 2024, 16:48:18 UTC
Previous filing
17 Jul 2024
Next filing
16 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $68,168 +16,667 +6.2% $4.09* 285,740 13 Aug 2024 Direct F1, F2
transaction RVMD Common Stock Sale $716,389 -16,667 -5.8% $42.98 269,073 13 Aug 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -16,667 -23% $0.000000 56,665 13 Aug 2024 Common Stock 16,667 $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
F2 Includes 95,476 restricted stock units.
F3 The transaction was executed in multiple trades in prices ranging from $42.76 to $43.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President, Research and Development